Sienna Biopharmaceuticals Overview
- Founded
-
2010
- Status
-
Public
- Employees
-
39
- Stock Symbol
-
SNNAQ
- Investments
-
1
Sienna Biopharmaceuticals General Information
Description
Sienna Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development, and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. The objective is to develop multi-asset pipeline of topical therapies that enhance the health, appearance, and quality of life of dermatology patients. The product portfolio includes SNA-120, SNA-125, and SNA-001.
Contact Information
Website
www.siennabio.com
Formerly Known As
Sienna Labs
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Stock Exchange
PINX
Primary Office
- 30699 Russell Ranch Road
- Suite 140
- Westlake Village, CA 91362
- United States
+1 (818) 000-0000
Sienna Biopharmaceuticals Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| 44.8K |
Sienna Biopharmaceuticals Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2019 | FY 2018 31-Dec-2018 | FY 2017 31-Dec-2017 | FY 2016 31-Dec-2016 |
|---|---|---|---|---|
| EV | (13,007) | 15,053 | 287,833 | |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (52,417) | (73,314) | (50,715) | (21,095) |
| Net Income | (47,951) | (73,471) | (50,545) | (21,162) |
| Total Assets | 43,492 | 107,306 | 136,847 | 62,377 |
| Total Debt | 0 | 30,125 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Sienna Biopharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Sienna Biopharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Sienna Biopharmaceuticals Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Sienna Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechno
Pharmaceuticals
Westlake Village, CA
39
As of 2019
00000
0000000000.
000000
dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sin
000000000000000
Nashville, TN
000
As of 0000
000.00
000000000
000.00
000000
ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore e
0000 000000000
Alameda, CA
000
As of 0000
00000
000000000
00000
Add Comparison
Sienna Biopharmaceuticals Competitors (2)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Harrow Health | Corporate Backed or Acquired | Nashville, TN | 000 | 000.00 | 000000000 | 000.00 |
| 00000000 | Formerly VC-backed | Alameda, CA | 000 | 00000 | 000000000 | 00000 |
Sienna Biopharmaceuticals Patents
Sienna Biopharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20190209472-A1 | Formulations for dermal delivery of polymer conjugates of indolocarbazole compounds with reduced exposure | Abandoned | 04-Dec-2017 | 00000000 | |
| EP-3621657-A1 | Uses of polymer conjugates of indolocarbazole compounds with reduced exposure | Withdrawn | 10-May-2017 | 000000000 | |
| EP-3600440-A1 | Reduced exposure conjugates modulating therapeutic targets | Withdrawn | 20-Mar-2017 | 000000000 | |
| US-20180071024-A1 | Enhanced efficacy and targeted topical delivery of drugs to skin with nanoparticles | Abandoned | 20-Mar-2015 | 0000000000 | |
| EP-3071211-A1 | Metastable silver nanoparticle composites with color indicating properties | Withdrawn | 18-Nov-2013 | A61L15/56 |
Sienna Biopharmaceuticals Executive Team (18)
Sienna Biopharmaceuticals Board Members (15)
| Name | Representing | Role | Since |
|---|---|---|---|
| Dennis Fenton Ph.D | Self | Board Member | 000 0000 |
| Donna Janson | Self | Board Member | 000 0000 |
| Frederick Beddingfield III | Sienna Biopharmaceuticals | Chief Executive Officer & Board Member | 000 0000 |
| James Hindman | Self | Board Member | 000 0000 |
| Keith Leonard Jr. | Self | Chairman & Board Member | 000 0000 |
Sienna Biopharmaceuticals Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Sienna Biopharmaceuticals Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000000 | 06-Dec-2016 | 0000000000 | 00000 | Biotechnology |